Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA, BRIM-3 Study Group
N Engl J Med. 2011 364 (26): 2507-16

PMID: 21639808 · PMCID: PMC3549296 · DOI:10.1056/NEJMoa1103782

MeSH Terms (19)

Adult Aged Aged, 80 and over Antineoplastic Agents Dacarbazine Disease-Free Survival Female Humans Indoles Intention to Treat Analysis Male Melanoma Middle Aged Mutation Proto-Oncogene Proteins B-raf Sulfonamides Survival Analysis Vemurafenib Young Adult

Connections (1)

This publication is referenced by other Labnodes entities: